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Abstract
Introduction Cartilage thickness and volume loss
measurements using quantitative magnetic resonance imaging
(qMRI) are suggested to detect significant cartilage changes
over short time intervals. We aimed to compare these two
different approaches looking at the global knee and subregions,
using data from an osteoarthritis (OA) multicentre randomised
clinical trial.
Methods Three hundred and fifty-five patients with symptomatic
knee OA were recruited for a two-year, double-blind,
randomised clinical trial evaluating the effect of 200 mg
licofelone twice daily and 500 mg naproxen twice daily on
cartilage loss, and 301 patients had baseline MRI. MRIs were
performed at baseline, 6, 12 and 24 months. Cartilage volume
and thickness in the global joint, medial and lateral
compartments, and central weight-bearing subregions of the
medial and lateral femoral condyles and tibial plateaus were
analysed. Data were analysed for the mean value imputed for
intent-to-treat (ITT-MVI) and statistical analyses were performed
using two-sample Student's t-test.
Results Cartilage mean thickness loss in the global joint, lateral
and medial compartments, as well as in medial compartments
stratified according to patients with or without meniscal
extrusion, was significantly less in the licofelone compared with
the naproxen group at 12 and 24 months. Interestingly, these
data were similar to those found when using cartilage volume
loss as an outcome. Although greater cartilage volume and
mean thickness loss was seen in central weight-bearing
subregions of the medial and lateral compartments compared
with the whole compartment and also in patients with meniscal
lesions/extrusion, suggesting good sensitivity to change, its high
standard deviation precluded for the condyles a high statistical
power and abrogated statistically significant differences
between the treatment groups.
Conclusions These data demonstrate that both the
measurement of cartilage thickness and that of cartilage volume
provide the same level of sensitivity to estimate cartilage loss in
a clinical trial. However, the potential of gaining statistical power
with the use of thickness/volume change in knee subregions as
an outcome seems negated by high inter-patient variability.
Moreover, there is no superiority in statistical power by selecting
patients with meniscal extrusion.
2D: two-dimensional; 3D: three-dimensional; DMOAD: disease modifying osteoarthritis drug; ITT: intent-to-treat; MRI: magnetic resonance imaging; 
MVI: mean value imputed; NSAID: non-steroidal anti-inflammatory drug; OA: osteoarthritis; qMRI: quantitative magnetic resonance imagingArthritis Research & Therapy    Vol 10 No 6    Raynauld et al.
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Introduction
Osteoarthritis (OA) is characterised by a number of structural
changes that include the progressive loss over time of articular
cartilage from the joint surfaces. Such loss has been evaluated
mainly by arthroscopic and histological assessments in pre-
clinical studies and with the use of X-rays in clinical studies.
These methods have been recognised as having significant
limitations, particularly in the assessment and quantification of
cartilage loss in observational studies following the evolution
of the disease, and in clinical trials with disease modifying OA
drugs (DMOADs).
A number of X-ray methods and techniques have been pro-
posed and recommended for use in the assessment of drug
effects in such trials [1-3]. Some success has been achieved
in various studies exploring the effects of drugs with DMOAD
activity by measuring the change in joint space width in the
medial compartment of the knee [1,4-8]. The low sensitivity to
change of the X-ray method, and the fact that the loss in joint
space width in OA could be related to structural changes
other than cartilage loss, such as the presence of meniscal
extrusion [9], have raised a number of issues regarding the use
of X-rays in such trials.
In recent years, the use of magnetic resonance imaging (MRI)
for the assessment of musculoskeletal structural changes has
expanded to include a number of new technologies that are
capable of quantitatively and precisely evaluating cartilage vol-
ume/thickness over the joint surface, allowing for three-dimen-
sional (3D) reconstruction mapping of the entire joint cartilage
[10,11]. A first-step approach through segmentation provides
a set of two-dimensional (2D) contours that, when followed by
a second step of a 3D reconstruction of the entire joint, allows
cartilage thickness and volume estimation in the whole joint, as
well as in the different compartments, topographical areas and
subregions [12].
These methods to assess cartilage volume/thickness can be
used in cross-sectional or longitudinal studies. In longitudinal
studies, quantitative MRI (qMRI) has been found to be capable
of precisely and reliably assessing changes in cartilage vol-
ume/thickness over time [11-21]. Moreover, studies have
demonstrated that in patients with knee OA, cartilage loss is
more severe in the weight-bearing areas of the medial femoral
condyles and tibial plateaus [12]. The rate of knee cartilage
loss in these patients as measured by MRI was also found to
be predictive of the subsequent need for an arthroplasty [22].
The most important question, however, is the usefulness of
these new investigative technologies in the context of multi-
centre clinical trials exploring the DMOAD effects of new
drugs. A first DMOAD study has just been completed and the
data of the 3D evaluation of cartilage volume loss in the major
knee compartments over time in the different treatment groups
have been reported [23]. The present report extends the find-
ings from this previous one, and explores in depth and com-
pares different methods of assessing cartilage loss over time
using qMRI in a DMOAD clinical trial. More specifically, the
sensitivity to change of two methods of measurement, mean
cartilage thickness and cartilage volume, was assessed in
order to gain insight into which method offers greater sensitiv-
ity to estimate cartilage loss over time and which method bet-
ter estimates differences between treatment groups.
We also explored whether the selective evaluation of subre-
gions where the greatest loss of cartilage occurs, i.e. the
weight-bearing areas of the condyles and plateaus, offers
more sensitivity to assess changes between treatment groups
than evaluation of the loss in the entire condyle, plateau or
compartment. These questions of assessing the impact of
DMOADs on knee structure are obviously of the utmost impor-
tance as they raise issues that cannot be answered solely by
observational longitudinal studies, which have been the main
focus of attention so far.
Materials and methods
The original study design and protocol have been previously
described in detail [23]. In this multicentre, randomised, dou-
ble-blind study comparing 200 mg licofelone (Merckle GmbH,
Ulm, Germany) twice daily with 500 mg naproxen (Ratiopharm
GmbH, Ulm, Germany) twice daily in patients with knee OA,
subjects were treated for 24 months. Naproxen was chosen as
a comparator treatment because it is one of the most com-
monly prescribed non-steroidal anti-inflammatory drugs
(NSAIDs) for the symptomatic treatment of knee OA. MRI was
performed at baseline, 6, 12, and 24 months. Intent-to-treat
(ITT) analysis was carried out by imputing the missing value to
the average change recorded (mean value imputed; ITT-MVI)
among patients within their corresponding treatment group at
a specific time point (6, 12 and 24 months), provided the
patients had at least a baseline MRI. Two methods of cartilage
measurement, volume and mean thickness, were used as pre-
viously described [10]. All patients provided written informed
consent before entering the study, which was conducted in
accordance with International Conference on Harmonisation
of Technical Requirements for Registration of Pharmaceuti-
cals for Human Use Guidelines for Good Clinical Practice, and
was administered by local and central institutional review
boards.
Briefly, MRI acquisition allows a 3D image of knee surfaces to
be produced. With the 3D surfaces of the femur and tibia, a
bone-to-cartilage interface and a cartilage-to-soft tissue inter-
face are generated. To enhance the accuracy of the numerical
processing, a specific coordinate system is used to represent
each surface, that is a 3D cylindrical coordinate system for the
femur and 3D space coordinate system for the tibia [10]. The
sampling used for the representation of these surfaces is inde-
pendent of the acquisition resolution. The choice of the 3D
coordinate system allows each point of cartilage measurementAvailable online http://arthritis-research.com/content/10/6/R129
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to be represented by two axes (x and y) along the cartilage sur-
face, while the third axis (z) is perpendicular. The cartilage
thickness is represented by the Euclidean distance (z)
between the bone-to-cartilage interface and the cartilage-to-
soft tissue interface at each sample. The cartilage volume is
derived from the thickness and location of both surfaces at
each sample location as previously described [10].
The change in volume and mean thickness over time was
obtained by subtracting the follow-up value (volume or mean
thickness) from the initial (baseline) value. The percentage of
cartilage loss was calculated by dividing the change (volume
or mean thickness) by the baseline value, and the cartilage
loss over time evaluated for the entire knee (global) and for
each of the medial and lateral compartments. It was also cal-
culated for: the subregions of the medial central condyle and
tibia (transversal slices) as described previously [12]; the lat-
eral central condyle and tibia (transversal slices); and the
medial compartment and medial central condyle and tibia
(transversal slices) stratified by the absence or presence of
meniscal extrusion.
The extent of meniscal extrusion on the medial or lateral edges
of the femorotibial joint space was evaluated for the anterior,
middle and posterior horns of the menisci in which 0 = no
extrusion, 1 = partial extrusion and 2 = complete extrusion with
no contact with the joint space (severe). The percentage of
cartilage loss in the medial compartment stratified by the
absence (0) or presence (1 or 2) of meniscal extrusion was
calculated as previously described [24].
Between treatment groups, variable changes at all time points
were assessed using a two-sample Student's t-test. All tests
were two-sided, and a p ≤ 0.05 was considered statistically
significant. All statistical analyses were performed using SAS
software, version 9.1 (SAS Institute Inc, Cary, NC).
Results
Three hundred and fifty-five patients were enrolled in the study
and randomly assigned to receive licofelone or naproxen [23].
Baseline characteristics of this population were previously
described [23] (mean age of 60 years, 68% female, average
BMI 32 kg/m2). Three hundred and one patients, 147 in the
licofelone group and 154 in the naproxen group, had a base-
line MRI (ITT).
The cartilage loss for the global, lateral and medial compart-
ments is presented in terms of absolute value (Table 1) and
percentage (Table 2) for both volume and mean thickness.
Both the volume and mean thickness methods produced sim-
ilar findings of cartilage loss in terms of absolute value and per-
centage in the global, lateral and medial compartments at each
time point. For example, at 24 months, the percentage of car-
tilage loss in the global compartment with the volume method
(licofelone mean ± standard deviation: -5.9 ± 2.2%, naproxen:
-7.3 ± 2.5%, p < 0.0001) provided similar findings to those
from the mean thickness method (licofelone: -5.4 ± 2.1%,
naproxen: -6.7 ± 2.4%, p < 0.0001). This was also the case
for the lateral compartment (volume: licofelone: -4.7 ± 3.0%,
naproxen: -6.0 ± 3.0%, p = 0.0002; mean thickness:
licofelone: -4.3 ± 2.7%, naproxen: -5.7 ± 2.8%, p < 0.0001)
and the medial compartment (volume: licofelone: -7.5 ± 3.7%,
naproxen: -8.8 ± 4.4%, p = 0.004; mean thickness: licofelone:
-6.6 ± 3.3%, naproxen: -8.0 ± 3.9%, p = 0.001).
Table 3 presents the absolute value of cartilage loss in the
medial central condyle and tibia (transversal slices) for both
the volume and mean thickness measurements. Data showed
no difference between the two methods for the medial central
tibia at each time point examined: 6, 12 and 24 months. How-
ever, a slight difference favouring the mean thickness was
observed between the two methods in the medial central con-
dyle at six months only (volume: licofelone: -34.0 ± 53.0,
naproxen: -41.3 ± 62.4, p = 0.271; mean thickness:
licofelone: -0.040 ± 0.083, naproxen: -0.061 ± 0.102, p =
0.056). Interestingly, for both volume and mean thickness in
the condyle there was no statistical significance between
treatment groups at 24 months, contrasting with data from the
whole medial compartment.
The results of the absolute value of cartilage loss in the lateral
central condyle and tibia (transversal slices) for both the vol-
ume and mean thickness measurements are described in
Table 4. At 24 months, a small trend favouring mean thickness
was observed in the central condyle (volume: licofelone: -35.1
± 60.9, naproxen: -46.3 ± 40.0, p = 0.062; mean thickness:
licofelone: -0.047 ± 0.096 naproxen: -0.067 ± 0.072, p =
0.040), whereas at 6 and 12 months both methods provided
similar findings. In the tibia, however, data strongly favoured
the volume method at 12 months (volume: licofelone: -44.7 ±
32.2, naproxen: -56.1 ± 32.9, p = 0.003; mean thickness:
licofelone: -0.124 ± 0.094, naproxen: -0.151 ± 0.095, p =
0.013), and 24 months (volume: licofelone: -71.9 ± 41.1,
naproxen: -85.8 ± 41.9 p = 0.004; mean thickness: licofelone:
-0.203 ± 0.120, naproxen: -0.232 ± 0.110, p = 0.032). Again,
and contrasting with the whole lateral compartment, in the
central condyle there was no statistical significance at 12
months between treatment groups.
The analyses stratified by the absence or presence of menis-
cal extrusion showed similar findings with the volume and
mean thickness measurements in the medial compartment
(Table 5). In the medial central condyle and tibia (transversal
slices) subregions stratified according to the absence or pres-
ence of meniscal extrusion, greater cartilage loss was found
for the volume (data not shown), although findings were also
similar with both methods.
Comparisons of findings using changes in percentage
between volume and mean thickness instead of the absoluteArthritis Research & Therapy    Vol 10 No 6    Raynauld et al.
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value (mm3) revealed that 92% of the findings were similar
with the two methods.
Discussion
This in-depth analysis provides interesting new information
about the potential and limits of different methods that can be
used to analyse data in the assessment of the evolution of car-
tilage loss and the response to treatment of patients with knee
OA in multicentre DMOAD clinical trials exploring and compar-
ing drug effects.
The first important question addressed was whether assess-
ing cartilage loss using the mean thickness approach offers
the same level of sensitivity to change as the cartilage volume
Table 1
Average of absolute value of cartilage loss in the global, lateral and medial compartments at 6, 12, and 24 months of follow-up
Volume (mm3) Mean thickness (mm)
Licofelone Naproxen p-value Licofelone Naproxen p-value
Global
6 mo -309.7 ± 238.9 -357.8 ± 320.3 0.140 -0.043 ± 0.034 -0.051 ± 0.047 0.093
12 mo -438.7 ± 252.9 -543.3 ± 287.3 0.0009 -0.061 ± 0.034 -0.078 ± 0.040 <0.0001
24 mo -701.6 ± 331.9 -853.2 ± 299.0 <0.0001 -0.095 ± 0.040 -0.119 ± 0.041 <0.0001
Lateral
6 mo -130.8 ± 143.7 -159.4 ± 143.4 0.085 -0.038 ± 0.041 -0.046 ± 0.043 0.091
12 mo -192.1 ± 146.1 -244.3 ± 168.2 0.004 -0.056 ± 0.041 -0.072 ± 0.049 0.002
24 mo -290.7 ± 184.2 -368.6 ± 161.4 0.0001 -0.080 ± 0.051 -0.105 ± 0.047 <0.0001
Medial
6 mo -178.9 ± 157.2 -198.3 ± 214.0 0.370 -0.047 ± 0.043 -0.056 ± 0.059 0.136
12 mo -246.6 ± 185.3 -299.0 ± 182.7 0.014 -0.064 ± 0.050 -0.084 ± 0.049 0.0006
24 mo -410.9 ± 229.9 -484.6 ± 237.1 0.007 -0.107 ± 0.053 -0.131 ± 0.061 0.0004
Values are presented as mean ± standard deviation. mo = months
Table 2
Average of percentage of cartilage loss in the global, lateral and medial compartments at 6, 12 and 24 months of follow-up
Volume (mm3) Mean thickness (mm)
Licofelone Naproxen p-value Licofelone Naproxen p-value
Global
6 mo -2.7 ± 1.9 -3.0 ± 3.2 0.250 -2.4 ± 1.9 -2.8 ± 2.9 0.203
12 mo -3.9 ± 2.0 -4.8 ± 2.5 0.0002 -3.5 ± 1.9 -4.5 ± 2.3 <0.0001
24 mo -5.9 ± 2.2 -7.3 ± 2.5 <0.0001 -5.4 ± 2.1 -6.7 ± 2.4 <0.0001
Lateral
6 mo -2.1 ± 2.3 -2.6 ± 2.6 0.092 -2.0 ± 2.2 -2.4 ± 2.5 0.125
12 mo -3.3 ± 2.4 -4.3 ± 3.2 0.001 -3.1 ± 2.1 -4.1 ± 2.9 0.0006
24 mo -4.7 ± 3.0 -6.0 ± 3.0 0.0002 -4.3 ± 2.7 -5.7 ± 2.8 <0.0001
Medial
6 mo -3.3 ± 2.9 -3.6 ± 5.0 0.560 -2.9 ± 2.7 -3.2 ± 4.3 0.383
12 mo -4.6 ± 3.2 -5.6 ± 3.5 0.009 -4.0 ± 3.0 -5.1 ± 3.2 0.001
24 mo -7.5 ± 3.7 -8.8 ± 4.4 0.004 -6.6 ± 3.3 -8.0 ± 3.9 0.001
Values are presented as mean ± standard deviation. mo = monthsAvailable online http://arthritis-research.com/content/10/6/R129
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approach. An initial observation was that the measurement of
cartilage volume changes in the global (entire) knee and
medial and lateral compartments provided exactly the same
level of sensitivity to estimate between-treatment comparative
changes in the therapeutic groups over the different time
points of the study. The findings were similar when the data
were analysed as absolute or relative (percentage) value of
cartilage loss. Overall, these results showed that both meth-
ods of assessment, that is measuring changes in cartilage vol-
ume or mean thickness, offer the same level of sensitivity to
evaluate cartilage loss at different times and to estimate the
effects of treatment. These findings are in line with the calcu-
lation of the correlation coefficients between the changes over
time of the two measurements, which are all greater than 0.90
(p < 0.0001, Pearson rho) regardless of the cartilage compart-
ment (global, medial or lateral), the time span (6, 12 or 24
months) or treatment group chosen. This is inherent in the
methodology because the cartilage volume and mean thick-
ness computations assess the cartilage in a very similar way.
The findings from the present study provide new information
on comparative results of data generated differently, a finding
that has not been reported before in the context of such stud-
ies. Previous observational longitudinal trials have employed
both methods to assess cartilage loss. Although some sug-
gestions have been made of the possible superiority of mean
thickness over cartilage volume assessment in such trials,
head-to-head data comparison has not been reported [25].
The present study provides a definite answer to that very
important question, not only in the context of a longitudinal
study, but more importantly in the context of a DMOAD trial
involving the assessment of changes over time within a patient
Table 3
Average of absolute value of cartilage loss (volume and mean thickness) in the medial central condyle and tibia at 6, 12 and 24 
months of follow-up
Volume (mm3) Mean thickness (mm)
Licofelone Naproxen p-value Licofelone Naproxen p-value
Condyle
6 mo -34.0 ± 53.0 -41.3 ± 62.4 0.271 -0.040 ± 0.083 -0.061 ± 0.102 0.056
12 mo -48.5 ± 52.4 -60.2 ± 52.0 0.053 -0.062 ± 0.085 -0.084 ± 0.082 0.020
24 mo -91.9 ± 74.9 -102.6 ± 73.9 0.215 -0.130 ± 0.107 -0.141 ± 0.109 0.370
Tibia
6 mo -41.8 ± 35.9 -40.5 ± 34.5 0.755 -0.099 ± 0.090 -0.097 ± 0.090 0.815
12 mo -55.8 ± 39.4 -68.7 ± 44.3 0.008 -0.134 ± 0.093 -0.166 ± 0.116 0.010
24 mo -77.4 ± 45.5 -101.9 ± 55.3 <0.0001 -0.182 ± 0.100 -0.239 ± 0.134 <0.0001
Values are presented as mean ± standard deviation. mo = months
Table 4
Average of absolute value of cartilage loss (volume and mean thickness) in the lateral central condyle and tibia at 6, 12 and 24 
months of follow-up
Volume (mm3) Mean thickness (mm)
Licofelone Naproxen p-value Licofelone Naproxen p-value
Condyle
6 mo -21.5 ± 44.2 -27.6 ± 40.7 0.210 -0.031 ± 0.073 -0.040 ± 0.078 0.299
12 mo -25.5 ± 47.6 -34.6 ± 44.7 0.088 -0.039 ± 0.077 -0.055 ± 0.081 0.078
24 mo -35.1 ± 60.9 -46.3 ± 40.0 0.062 -0.047 ± 0.096 -0.067 ± 0.072 0.040
Tibia
6 mo -33.3 ± 33.2 -32.8 ± 39.3 0.899 -0.091 ± 0.098 -0.090 ± 0.110 0.940
12 mo -44.7 ± 32.2 -56.1 ± 32.9 0.003 -0.124 ± 0.094 -0.151 ± 0.095 0.013
24 mo -71.9 ± 41.1 -85.8 ± 41.9 0.004 -0.203 ± 0.120 -0.232 ± 0.110 0.032
Values are presented as mean ± standard deviation. mo = monthsArthritis Research & Therapy    Vol 10 No 6    Raynauld et al.
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treatment group, as well as between study arms. As men-
tioned above, the cartilage volume calculation being derived
from the cartilage thickness, the good correlation between
these two methods of measurement was therefore not unex-
pected.
Another important issue to be addressed in the context of
DMOAD trials is whether concentrating on the analysis of car-
tilage changes in the subregions, where the greatest loss of
cartilage is found on the condyles and plateaus, would provide
a better chance of finding significant differences between
treatment groups and allow these differences to be observed
earlier in the course of the trial. The results from longitudinal
observational studies are certainly supportive of such an
hypothesis [11,12,21,26]. However, in the present study, the
selective measurement of the loss of cartilage volume and
mean thickness in the central weight-bearing zones of the
medial femoral condyles and tibial plateaus demonstrated
greater loss, but also greater variability in results. This is well
illustrated on the condyles where statistically significant differ-
ences between the two drugs were found at 12 months but
not at 24 months. These data contrast with those from the
analysis of the global knee and the medial and lateral compart-
ments, in which significant differences between treatment
groups were observed at both 12 and 24 months. These find-
ings are important, particularly in the context of a DMOAD clin-
ical trial in which the classical primary outcome is based on
measuring the loss of cartilage in the medial compartment.
Overall, the results of the lateral compartment are interesting,
as data from the volume loss show progressive, statistically
significant loss of cartilage, although less significant than from
the medial compartment. The change in the lateral compart-
ment could eventually be useful as a secondary outcome in
DMOAD studies. Data on the lateral central condyle are again
supportive of the fact that the analysis of specific regions with
greater cartilage loss offers no advantage over the classical
approach of analysis by compartment.
Research questions based on an a priori hypothesis as to
which area of the knee may show the greatest cartilage loss
are difficult to answer. OA disease progression variability is
such that any chosen knee subregion may not reflect, for a
specific patient, the greatest cartilage loss over time. This is
not a problem when a broader area of cartilage assessment is
chosen, such as the global knee or the compartments.
Previous reports from longitudinal observational studies have
stressed the fact that in patients with knee OA the presence
of meniscal lesions or extrusion is among the most important
risk factors of cartilage loss [24,27]. The results from the
present study extend these findings. A greater difference
between treatment groups was seen in the absence of menis-
cal extrusion at 12 and 24 months. Meniscal extrusion could
therefore be of importance in the context of clinical trials
because it may potentially be used for stratification of patients
or as an inclusion/exclusion criterion, which may theoretically
impede the evaluation of the potential of a new DMOAD treat-
ment. The analysis of data from patients without medial menis-
cal extrusion showed a difference in the loss of cartilage in the
medial compartment between the two treatment groups with a
trend at six months and a significant difference at 12 and 24
months. These findings may indicate that greater sensitivity to
change can be achieved by selecting patients without medial
meniscal extrusion, although caution should be exercised at
this time with regard to these findings. Patients with meniscal
extrusion usually lose more cartilage volume/thickness over
time, so these findings are in line with those data previously
described for the central weight-bearing subregions. Again,
higher inter-patient variability could very well explain these dif-
ferences.
Table 5
Average of absolute value of cartilage loss (volume and mean thickness) in the medial compartment stratified by the absence or 
presence of meniscal extrusion at 6, 12 and 24 months of follow-up
Volume (mm3) Mean thickness (mm)
Licofelone Naproxen p-value Licofelone Naproxen p-value
Absence of meniscal extrusion
6 mo -143.5 ± 126.7 -163.7 ± 211.1 0.399 -0.038 ± 0.036 -0.046 ± 0.057 0.203
12 mo -198.8 ± 152.1 -253.7 ± 134.6 0.007 -0.051 ± 0.042 -0.072 ± 0.036 0.0003
24 mo -366.2 ± 192.8 -437.2 ± 174.3 0.006 -0.096 ± 0.049 -0.118 ± 0.044 0.0006
Presence of meniscal extrusion
6 mo -239.9 ± 184.9 -293.8 ± 194.0 0.171 -0.062 ± 0.049 -0.082 ± 0.057 0.076
12 mo -329.0 ± 208.5 -423.9 ± 234.9 0.040 -0.085 ± 0.054 -0.117 ± 0.063 0.011
24 mo -488.0 ± 267.3 -615.2 ± 325.9 0.040 -0.128 ± 0.055 -0.166 ± 0.084 0.013
Values are presented as mean ± standard deviation. mo = monthsAvailable online http://arthritis-research.com/content/10/6/R129
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More information gathered from future studies is needed
before a final conclusion can be reached. Again, both methods
of measurement, that is the percentage of cartilage volume
loss and mean thickness loss, were found to provide the same
level of accuracy to estimate the differences between the two
treatment groups. It is noteworthy that elapsed time is impor-
tant for the MRI changes because the most significant
changes for both measurement techniques were seen after
two years. In previous studies [16,28], we demonstrated that
if the cartilage changes of a cohort over time are examined,
statistically significant results are seen in as early as six
months of follow-up. However, the data at six months shown
here do not demonstrate statistical significance between the
two treatment groups. According to the data presented, it
would appear that a window of at least one year is necessary
to see a clear separation between the treatment groups. This
may be true for the present comparators, that is licofelone
compared with naproxen. However, we would not suggest that
a one-year study is sufficient for any knee OA clinical trial
because comparing treatments that slow down cartilage pro-
gression in a similar way may need a longer time span or a
much larger number of patients enrolled to show statistical
and clinical significance.
Conclusion
The findings of this study demonstrate that, in the context of
DMOAD trials in patients with knee OA, the measurement of
cartilage loss estimated as either the change in volume or the
change in mean thickness provides the same level of sensitiv-
ity to assess cartilage loss over time, as well as differences
between treatment groups. Selection of patients with the
greatest loss of cartilage based on certain risk factors such as
meniscal extrusion, should be carefully considered, because it
may not necessarily provide a better chance of identifying dif-
ferences between treatment groups. The group with the more
rapid progression of cartilage loss also presented higher vari-
ability between patients, as indicated by the greater standard
deviation in this group. Moreover, the findings indicate that in
the context of such DMOAD trials, strategies to select high-
risk patients and/or to selectively analyse the subregions with
greater cartilage loss, do not, in contrast to results from longi-
tudinal observational studies, provide greater sensitivity to
change and, therefore, do not provide any advantage over the
use of a general patient cohort combined with the analysis of
cartilage loss in the global knee or in the compartments.
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